Why Aptose Biosciences Plunged 45% Yesterday

Aptose Biosciences (TSX:APT)(NASDAQ:APTO) results for its leukemia drug were met with a poor reaction, sending shares down 45%.

| More on:

Aptose Biosciences (TSX:APT)(NASDAQ:APTO) shares crashed 45% on Tuesday after results from its leukemia trial were met with a less-than-ideal reaction.

What happened?

The biotechnology company focused on oncology reported its oral, once-daily myeloid kinome inhibitor (MKI) phase-one-of-two study. The company believes it showed “meaningful benefit in all responders” in the 34-patient study. It’s a difficult area of study, as acute myelogenous leukemia (ACL) relapses are incredibly difficult to treat.

Its current trial, named luxeptinib, aims at creating a “next generation” formula, to “reduce pill burden, improve absorption, and increase exposure.” The new formula aims to begin testing by the first half of 2022.

The news became public on Monday evening, sending shares in a downward spiral almost immediately. Shares reached a trough price, down 45% on Tuesday. Shares currently trade at $1.44 as of writing.

So what?

This new study continues the bad share news for Aptose, despite analysts continuing to recommend it as a strong buy. It seems that investors don’t want to wait for action and remain unconvinced for a while now. The last report back in June was also met with lukewarm results.

The problem is that it’s been far too much waiting for investors regarding Aptose. Everyone wants the next big thing after the COVID-19 vaccine. A treatment for cancer would certainly be a great place to look. However, Aptose continues to see more trials and small results.

Now what?

Analysts are of mixed minds when it comes to Aptose. On the one hand, it could be a good momentum buy if you’re watching it like a hawk. On the other hand, it’s not valuable at the moment. Its fundamentals are weak, with a -1.93 EV/EBITDA and price-to-book ratio of two. Further, it continues to operate at a loss, with its most recent earnings coming in at a loss of $55 million. And that loss has grown larger and larger as the quarters continue on.

If Aptose can’t convince investors that its next drug is worth the wait soon, it may be out of long-term luck. So, I wouldn’t look at this week’s collapse in share price as an opportunity. I’d definitely wait and see what happened in 2022 before buying even a share of Aptose.

Shares of Aptose are down 75% year to date.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Investing

ways to boost income
Dividend Stocks

3 Low-Volatility Growth Stocks for Promising Returns

Conservative investors may prefer low-volatility and consistent growth stocks over explosive but relatively risky picks.

Read more »

ETF chart stocks
Dividend Stocks

Turn a $15,000 TFSA Into $40,505.97 With This ETF

Making money can seem so difficult, but if you find the right ETF and reinvest dividends for the long term,…

Read more »

Doctor talking to a patient in the corridor of a hospital.
Investing

What to Know About Canadian Healthcare Stocks for 2025

These two companies are prime examples of Canada's healthcare sector. Here's what to know about where these stocks may be…

Read more »

A worker gives a business presentation.
Investing

Spotlight on Potential: 2 Mid-Cap Stocks Ready for a Remarkable Comeback in 2025

Badger Infrastructure Solutions (TSX:BDGI) and another top mid-cap stock are still capable of big growth.

Read more »

Canada national flag waving in wind on clear day
Dividend Stocks

TFSA: 3 Canadian Stocks to Buy and Hold for the Long Run

These top TSX stocks pay attractive dividends for TFSA investors seeking reliable passive income.

Read more »

Canadian Dollars bills
Tech Stocks

Invest $30,000 in 2 TSX Stocks, Create $9,265.20 in Passive Income

If you're only going to invest in two TSX stocks, invest in these top choices that have billionaires backing them…

Read more »

hand stacking money coins
Dividend Stocks

Want Decades of Passive Income? 3 Stocks to Buy Right Now

These Canadian stocks have been consistently rewarding shareholders with regular dividend payouts for decades.

Read more »

A plant grows from coins.
Investing

3 Top Growth Stocks to Buy for December

Here are three top Canadian growth stocks long-term investors may want to consider adding before the end of the year.

Read more »